Intranasal injection of recombinant human erythropoietin improves cognitive and visual impairments in chronic cerebral ischemia rats

Abstract

The present study aimed to study the protective effect of intranasally delivered recombinant human erythropoietin (rhEPO) on cognitive and visual impairments in a permanent bilateral common carotid artery occlusion (2VO)-induced chronic cerebral ischemia (CCI) rat model. Male Sprague-Dawley rats (age, 6 months) with 2VO-induced CCI were treated with intranasal rhEPO (50 U/100 g) once per week for 8 weeks. A Morris water maze was used to evaluate the spatial learning and memory of the rats. Flash visual evoked potentials were measured to assess retinal function. Hematoxylin and eosin staining was performed to visualize and evaluate histopathological changes in the cerebral cortex, the hippocampus CA1 region and the retina. CCI-induced learning, memory and visual impairments were significantly alleviated in rats treated with rhEPO compared with those treated with a saline vehicle control. This was evidenced by remarkably decreased escape latency, increased frequency of crossing the hidden platform and elevated amplitude of primary wave in the rats treated with rhEPO. In addition, the rats experienced CCI-induced histopathological alterations, demonstrated by thinning of the cerebral cortex and retina, and losses of neurons and retinal ganglion cells. These alterations were significantly reversed in response to rhEPO administration compared with the saline vehicle control group. rhEPO may exert a protective role against cognitive and visual impairments in rats with CCI at least partially through preventing the thinning of the cerebral cortex and retina, as well as by inhibiting the loss of neurons and retinal ganglion cells.

Intranasal Resveratrol Nanoparticles Enhance Neuroprotection in a Model of Multiple Sclerosis

“…For example, we treated the same animal model with intranasal ST266, a progenitor cellproduced therapy containing numerous growth factors and cytokines, and found significant RGC neuroprotective as well as optic nerve anti-inflammatory effects with this complex therapy [6,16], further supporting the idea that combined anti-inflammatory and neuroprotective therapies may be useful to attenuate optic neuritis. Zhou et al also showed that intranasal erythropoietin improves both cognitive and visual function in a cerebral ischemia rodent model [17]. Few, if any, other groups have examined intranasal drug delivery for treating optic neuropathies; however, intranasal delivery has been shown to bypass the blood-brain barrier for targeting central nervous system disease [18,19], including studies showing the potential effects of intranasal RSV on Alzheimer's disease [20].…”

Repurposing ibuprofen-loaded microemulsion for the management of Alzheimer’s disease: evidence of potential intranasal brain targeting

“…All groups received 100 ml tested formulation, with 2.0 mg ibuprofen or blank. A nasal installation volume of 100 ml was considered as an acceptable delivery volume in rats (Zhou et al, 2020). The dose was calculated according to the lowest oral bioavailability dose in adult humans of 400 mg/tablet (in t ' Veld et al, 2001).…”